Payment overview · 2025
General Payments
$259.58
5 reported records · 4 companies
Healthcare provider profile · identity verified
Arshad Pervez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WYANDOTTE, MI · NPI 1023002987
Verified facts
What the public records show
CMS Open Payments records show Arshad Pervez, M.D. received $259.58 in general payments during 2025 across 5 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 41.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.03 | 41.6% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $90.94 | 35.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $30.89 | 11.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.72 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $259.58 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $94.25 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $90.94 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $30.89 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 474 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 442 | 143 |
| Losartan Potassium | Losartan Potassium | 412 | 132 |
| Omeprazole | Omeprazole | 229 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 206 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 196 | 75 |
| Metformin Hcl | Metformin Hcl | 188 | 61 |
| Lisinopril | Lisinopril | 173 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 171 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 146 | 42 |
| Furosemide | Furosemide | 136 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 59 |
| Eliquis | Apixaban | 113 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 97 | 13 |
| Carvedilol | Carvedilol | 95 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 33 |
| Allopurinol | Allopurinol | 79 | 21 |
| Simvastatin | Simvastatin | 79 | 21 |
| Azithromycin | Azithromycin | 67 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 15 |
| Methocarbamol | Methocarbamol | 58 | 23 |
| Mirtazapine | Mirtazapine | 58 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 17 |
| Alprazolam | Alprazolam | 56 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 21 |
| Gabapentin | Gabapentin | 54 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 20 |
| Bumetanide | Bumetanide | 52 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 19 |
| Montelukast Sodium | Montelukast Sodium | 51 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | 14 |
| Atenolol | Atenolol | 43 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | 16 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Prednisone | Prednisone | 41 | 27 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Lorazepam | Lorazepam | 40 | 11 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 15 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | 11 |
| Potassium Chloride | Potassium Chloride | 34 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | 11 |
| Famotidine | Famotidine | 32 | 21 |
| Spironolactone | Spironolactone | 31 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 24 |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 24 |
| Cephalexin | Cephalexin | 27 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Lactulose | Lactulose | 25 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 20 |
| Ibuprofen | Ibuprofen | 24 | 14 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Levetiracetam | Levetiracetam | 22 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $259.58 · 5 records | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE, LEQVIO, LifeVest, WATCHMAN FLX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error